Untangling the difficult interplay between ischemic and hemorrhagic risk: The role of risk scores
- PMID: 35316974
- PMCID: PMC8900521
- DOI: 10.4330/wjc.v14.i2.96
Untangling the difficult interplay between ischemic and hemorrhagic risk: The role of risk scores
Abstract
Background: Bleedings are an independent risk factor for subsequent mortality in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention. This represents a hazard equivalent to or greater than that for recurrent ACS. Dual antiplatelet therapy (DAPT) represents the cornerstone in the secondary prevention of thrombotic events, but the benefit of such therapy is counteracted by the increased hemorrhagic complications. Therefore, an early and individualized patient risk stratification can help to identify high-risk patients who could benefit the most from intensive medical therapies while minimizing unnecessary treatment complications in low-risk patients.
Aim: To review existing literature and gain better understanding of the role of ischemic and hemorrhagic risk scores in patients with ischemic heart disease (IHD).
Methods: We used a combination of terms potentially used in literature describing the most common ischemic and hemorrhagic risk scores to search in PubMed as well as references of full-length articles.
Results: In this review we briefly describe the most important ischemic and bleeding scores that can be adopted in patients with IHD, focusing on GRACE, CHA2DS2-Vasc, PARIS CTE, DAPT, CRUSADE, ACUITY, HAS-BLED, PARIS MB and PRECISE-DAPT score. In the second part of this review, we try to define a possible approach to the IHD patient, using the most suitable scores to stratify patient risk and decide the most appropriate patient treatment.
Conclusion: It becomes evident that risk scores by themselves can't be the solution to balance the ischemic/bleeding risk of an IHD patient. Instead, some risk factors that are commonly associated with an elevated risk profile and that are already included in risk scores should be the focus of the clinician while he/she is taking care of a patient affected by IHD.
Keywords: Acute coronary syndrome; Bleeding; Ischemic heart disease; Mortality; Percutaneous coronary intervention; Risk score.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors declare no potential conflicts of interest.
Similar articles
-
Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome.Rev Esp Cardiol (Engl Ed). 2019 Mar;72(3):215-223. doi: 10.1016/j.rec.2018.06.004. Epub 2018 Jul 18. Rev Esp Cardiol (Engl Ed). 2019. PMID: 30029980 English, Spanish.
-
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor.Int J Cardiol. 2020 Feb 15;301:200-206. doi: 10.1016/j.ijcard.2019.11.132. Epub 2019 Nov 22. Int J Cardiol. 2020. PMID: 31785951
-
Performance of HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention.J Cardiol. 2019 Jun;73(6):479-487. doi: 10.1016/j.jjcc.2018.10.013. Epub 2018 Dec 28. J Cardiol. 2019. PMID: 30598387
-
Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.Clin Ther. 2020 Oct;42(10):2084-2097. doi: 10.1016/j.clinthera.2020.08.003. Epub 2020 Aug 29. Clin Ther. 2020. PMID: 32873416 Review.
-
Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.J Thromb Thrombolysis. 2020 Aug;50(2):337-354. doi: 10.1007/s11239-019-02033-2. J Thromb Thrombolysis. 2020. PMID: 31919736
References
-
- Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200–1206. - PubMed
-
- Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–782. - PubMed
-
- Baber U, Kovacic J, Kini AS, Sharma SK, Dangas G, Mehran R. How serious a problem is bleeding in patients with acute coronary syndromes? Curr Cardiol Rep. 2011;13:312–319. - PubMed
-
- Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J. 2003;24:1815–1823. - PubMed
-
- Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362–1368. - PubMed